Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition comprising the anti-4-1bb antibody for treating or preventing rheumatoid arthritis

A rheumatoid, composition technology, applied in the direction of drug combination, antibody, anti-animal/human immunoglobulin, etc., can solve the problems of hypotonia, hyperpigmentation, etc.

Inactive Publication Date: 2010-06-02
UNIV OF ULSAN FOUND FOR IND COOPERATION
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most of the effective steroid hormones have been reported to have various side effects such as hyperpigmentation, amenorrhea, acne, dystonia, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition comprising the anti-4-1bb antibody for treating or preventing rheumatoid arthritis
  • Pharmaceutical composition comprising the anti-4-1bb antibody for treating or preventing rheumatoid arthritis
  • Pharmaceutical composition comprising the anti-4-1bb antibody for treating or preventing rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] [Example 1] Preparation of Antibody

[0058] Hybridoma cells producing 4-1BB (3H3) and 4-1BB (TKL-1) antibodies were kindly provided by Drs. Robert Mittler (Emory university, Atlanta, Georgia) and Hideo Yagita and Ko Okumura (Juntendo university, Tokyo, Japan), respectively. Antibodies were purified from Ehrlich ascites carcinoma cells by protein G-column (sigma, St. Louis, Missouri). LAL (Cambrex, Walkersville, Maryland) measured endotoxin levels below 0.05 units, and the binding activity of mAbs was tested in anti-CD3 mAb-stimulated T cells or 4-1BBL-transfected P815 cells. F(ab') of 3H3 was purified using a Sephacryl s-200HR column (sigma) after digesting the antibody with pepsin 2 Fragment, purified mouse IgG purchased from Sigma was used as a control antibody. Subsequent mAbs were purchased from BDPharMingen (San Diego, California) for flow cytometric analysis: FITC-, PE-.PerCP-, and biotin-anti-CD8 (53-6.7); PE-anti-CD4 (GK1. 5); PE- and biotin-anti-CD11c (HL3)...

Embodiment 2

[0059] [Example 2] CIA induction and anti-4-1BB treatment

[0060] To understand the role of 4-1BB in the CIA process, it was examined whether an agonistic anti-4-1BB antibody (3H3) or a blocking anti-4-1BB ligand could alter the CIA process.

[0061] CIA was induced by intradermal injection of 100D CFA-emulsified bovine collagen II (CII) (Chondrex, Redmond, Washington) into the base of the tail of 6-7 week old DBA / 1 male mice. Antigen was replenished by M. tuberculosis H37RA (2.0 mg / ml, Chondrex). Inflammation of the mouse joints was examined daily and scored as follows: 0, normal; 1, erythema and mild swelling confined to the ankle joint; 2, erythema and mild swelling extending outside the ankle joint; 3 , erythema and moderate swelling extending beyond the ankle joint; 4, erythema and severe swelling extending beyond the ankle joint; the maximum arthritis score per paw was 4, while the maximum disease score per mouse was 16.

[0062] Mice treated with control IgG develope...

Embodiment 3

[0063] [Example 3] Histology and immunostaining

[0064] Immunogenic hind paws were fixed in 10% formalin, decalcified and mounted in paraffin. Joint sections (5-7D) were prepared and stained with hematoxylin and eosin by conventional methods. Sections were examined by light microscopy. For double fluorescent staining, the purified CD11c + CD8 + T cells were incubated on L-lysine-coated slides at 37°C for 1 hour. Subsequent blocking was performed with 1D unlabeled 2.4G2 anti-FcyR Ab (BD PharMingen). Cells were stained with FITC-anti-CD3 plus PE-anti-CD8 or FITC-anti-CD3 plus PE-anti-CD11c or FITC-anti-CD8 plus PE-anti-CD11c. After final washing, slides were mounted on GVA use racks (Zymed, San Francisco, California) and viewed using a laser scanning confocal microscope (FV500, Olympus, Tokyo, Japan). For immunostaining of DLN, DLN sections (8D) were washed with PBS and stained with FITC-anti-CD3 plus PE-anti-CD11c or FITC-anti-CD8 plus PE-anti-CD11c. Slides were process...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is related to a pharmaceutical composition comprising anti-4-lBB antibody as an active ingredient in an amount effective to preventing and treating rheumatic arthritic diseases by proliferating CDl Ic<+>CD8<+> T cells and inducing CD4<+> T cell suppression, together with a pharmaceutically acceptable carrier. The composition of the present invention is not toxic in general immune response and can remarkably alleviate progressive, inflammatory or auto-immune arthritis symptoms by inducing antigen- specific immune suppression. Accordingly, it can be useful in the prevention or treatment of arthritic diseases without adverse response.

Description

technical field [0001] The present invention relates to a pharmaceutical composition, which contains a pharmaceutical composition for treating and preventing rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (RA), is a chronic, degenerative systemic inflammatory disease characterized by joint hyperplasia and production of inflammatory cells, intra-articular fibrin deposition, and in its advanced stages, cartilage and bone breakdown . Although the etiology of RA remains debated, the sequence of events in the pathogenesis of the disease and the mechanisms of end-stage effects appear to have been established. CD4 + Helper T cells control the initial inflammatory damage. Macrophages of the synovial lining cells and synovial fibroblasts proliferate and express a large number of class II major histocompatibility complexes (MHC). Activated helper T cells appear to drive B cells to infiltrate the synovium to produce immunoglobulins. The specificity of mos...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K39/44C07K16/28
CPCA61K2039/505C07K16/2878A61P29/00A61K39/395A61K39/44
Inventor 权炳世
Owner UNIV OF ULSAN FOUND FOR IND COOPERATION